{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:39:59Z","timestamp":1793173199319,"version":"4.5.0"},"reference-count":178,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Vaccines are cost-effective tools for reducing morbidity and mortality caused by infectious diseases. The rapid evolution of pneumococcal conjugate vaccines, the introduction of tetravalent meningococcal conjugate vaccines, mass vaccination campaigns in Africa with a meningococcal A conjugate vaccine, and the recent licensure and introduction of glycoconjugates against<jats:italic>S.<\/jats:italic>Typhi underlie the continued importance of research on glycoconjugate vaccines. More innovative ways to produce carbohydrate-based vaccines have been developed over the years, including bioconjugation, Outer Membrane Vesicles (OMV) and the Multiple antigen-presenting system (MAPS). Several variables in the design of these vaccines can affect the induced immune responses. We review immunogenicity studies comparing conjugate vaccines that differ in design variables, such as saccharide chain length and conjugation chemistry, as well as carrier protein and saccharide to protein ratio. We evaluate how a better understanding of the effects of these different parameters is key to designing improved glycoconjugate vaccines.<\/jats:p>","DOI":"10.3389\/fmolb.2023.1201693","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T11:36:07Z","timestamp":1684236967000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines"],"prefix":"10.3389","volume":"10","author":[{"given":"Francesca","family":"Micoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Stefanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calman A.","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1046\/j.1469-0691.2003.00530.x","article-title":"Carbohydrate-protein conjugate vaccines","volume":"9","author":"Ada","year":"2003","journal-title":"Clin. Microbiol. Infect."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.vaccine.2003.11.061","article-title":"Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE)","volume":"22","author":"Alexander","year":"2004","journal-title":"Vaccine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.4049\/jimmunol.164.3.1625","article-title":"Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses","volume":"164","author":"Alexander","year":"2000","journal-title":"J. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/0264-410x(93)90172-t","article-title":"Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide","volume":"11","author":"Alonso De Velasco","year":"1993","journal-title":"Vaccine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.4049\/jimmunol.170.12.6165","article-title":"Proteins and their derived peptides as carriers in a conjugate vaccine for Streptococcus pneumoniae: Self-heat shock protein 60 and tetanus toxoid","volume":"170","author":"Amir-Kroll","year":"2003","journal-title":"J. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.1016\/j.vaccine.2011.08.019","article-title":"Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity","volume":"29","author":"An","year":"2011","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1172\/JCI111976","article-title":"Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197","volume":"76","author":"Anderson","year":"1985","journal-title":"J. Clin. Invest."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.4049\/jimmunol.137.4.1181","article-title":"Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: Structural and temporal requirements for priming in the human infant","volume":"137","author":"Anderson","year":"1986","journal-title":"J. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.142.7.2464","article-title":"Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197","volume":"142","author":"Anderson","year":"1989","journal-title":"J. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0189100","DOI":"10.1371\/journal.pone.0189100","article-title":"The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi","volume":"12","author":"Arcuri","year":"2017","journal-title":"Plos One"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1086\/509619","article-title":"Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom","volume":"194","author":"Auckland","year":"2006","journal-title":"J. Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S598","DOI":"10.1093\/clinids\/11.supplement_3.s598","article-title":"Pneumococcal polysaccharide vaccines","volume":"11","author":"Austrian","year":"1989","journal-title":"Rev. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/nm.2535","article-title":"A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design","volume":"17","author":"Avci","year":"2011","journal-title":"Nat. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1084\/jem.50.4.533","article-title":"Chemo-immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic sugar-protein antigens","volume":"50","author":"Avery","year":"1929","journal-title":"J. Exp. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.1128\/IAI.72.8.4884-4887.2004","article-title":"N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines","volume":"72","author":"Baraldo","year":"2004","journal-title":"Infect. Immun."},{"key":"B16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0065-3101(24)00217-2","article-title":"Human immune responses to polysaccharide antigens: An analysis of bacterial polysaccharide vaccines in infants","volume":"32","author":"Barrett","year":"1985","journal-title":"Adv. Pediatr."},{"key":"B17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0264-410x(94)00007-a","article-title":"Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide","volume":"13","author":"Bartoloni","year":"1995","journal-title":"Vaccine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1128\/IAI.69.7.4698-4701.2001","article-title":"Synthetic polysaccharide type 3-related di-tri-and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice","volume":"69","author":"Benaissa-Trouw","year":"2001","journal-title":"Infect. Immun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"9015","DOI":"10.1039\/c8cs00495a","article-title":"Antimicrobial glycoconjugate vaccines: An overview of classic and modern approaches for protein modification","volume":"47","author":"Berti","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.coi.2020.03.015","article-title":"Improving efficacy of glycoconjugate vaccines: From chemical conjugates to next generation constructs","volume":"65","author":"Berti","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1128\/IAI.37.1.15-22.1982","article-title":"Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates","volume":"37","author":"Beuvery","year":"1982","journal-title":"Infect. Immun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0264-410x(83)90010-5","article-title":"Physicochemical and immunological characterization of meningococcal group A polysaccharide-tetanus toxoid conjugates prepared by two methods","volume":"1","author":"Beuvery","year":"1983","journal-title":"Vaccine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.4049\/jimmunol.180.4.2165","article-title":"The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response","volume":"180","author":"Blanchard Rohner","year":"2008","journal-title":"J. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1586\/erv.11.14","article-title":"Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy","volume":"10","author":"Blanchard-Rohner","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"B25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s1074-7613(00)80333-7","article-title":"B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation","volume":"6","author":"Borriello","year":"1997","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1086\/344324","article-title":"Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom","volume":"186","author":"Borrow","year":"2002","journal-title":"J. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1128\/iai.71.10.5549-5555.2003","article-title":"Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom","volume":"71","author":"Borrow","year":"2003","journal-title":"Infect. Immun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","article-title":"Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: Use as a conjugation protein in vaccines and other potential clinical applications","volume":"39","author":"Broker","year":"2011","journal-title":"Biologicals"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1002\/chem.200400074","article-title":"The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein","volume":"10","author":"Buskas","year":"2004","journal-title":"Chemistry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0928-8244(03)00346-8","article-title":"Effect of conjugation methodology on the immunogenicity and protective efficacy of meningococcal group C polysaccharide-P64k protein conjugates","volume":"40","author":"Carmenate","year":"2004","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1128\/IAI.65.12.4918-4925.1997","article-title":"A strategy for rational design of fully synthetic glycopeptide conjugate vaccines","volume":"65","author":"Chong","year":"1997","journal-title":"Infect. Immun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1128\/IAI.40.1.245-256.1983","article-title":"Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates","volume":"40","author":"Chu","year":"1983","journal-title":"Infect. Immun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1128\/CVI.00336-07","article-title":"Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine","volume":"15","author":"Clutterbuck","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1365-2567.2006.02436.x","article-title":"The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine","volume":"119","author":"Clutterbuck","year":"2006","journal-title":"Immunology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S1473-3099(20)30488-6","article-title":"Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: A phase 1, dose-escalating, single-blind, randomised, placebo-controlled study","volume":"21","author":"Cohen","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1586\/erv.10.147","article-title":"Menveo\u00ae): A novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y","volume":"10","author":"Cooper","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/s0264-410x(98)00348-x","article-title":"Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines","volume":"17","author":"Costantino","year":"1999","journal-title":"Vaccine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1517\/17460441.2011.609554","article-title":"The design of semi-synthetic and synthetic glycoconjugate vaccines","volume":"6","author":"Costantino","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"key":"B39","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/0264-410x(92)90091-w","article-title":"Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C","volume":"10","author":"Costantino","year":"1992","journal-title":"Vaccine"},{"key":"B40","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1016\/j.vaccine.2017.09.055","article-title":"Investigating the candidacy of a capsular polysaccharide-based glycoconjugate as a vaccine to combat Haemophilus influenzae type a disease: A solution for an unmet public health need","volume":"35","author":"Cox","year":"2017","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/jphp.12321","article-title":"Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins","volume":"67","author":"Cuccui","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1128\/CVI.00266-09","article-title":"Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates","volume":"17","author":"Cui","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/01.inf.0000109221.50972.53","article-title":"Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants","volume":"23","author":"Dagan","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1097\/00006454-199711000-00010","article-title":"Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens","volume":"16","author":"Dagan","year":"1997","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B45","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1086\/514063","article-title":"Infant immunization with pneumococcal CRM197 vaccines: Effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines","volume":"176","author":"Daum","year":"1997","journal-title":"J. Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1128\/IAI.63.3.961-968.1995","article-title":"Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines","volume":"63","author":"De Velasco","year":"1995","journal-title":"Infect. Immun."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.4049\/jimmunol.145.9.3071","article-title":"Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine","volume":"145","author":"Donnelly","year":"1990","journal-title":"J. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1002\/1521-4141(200112)31:12<3816::AID-IMMU3816>3.0.CO;2-K","article-title":"Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: A model for new conjugate vaccines","volume":"31","author":"Falugi","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.vaccine.2003.11.034","article-title":"Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: From the lab bench to phase III clinical trials","volume":"22","author":"Fattom","year":"2004","journal-title":"Vaccine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/0264-410x(95)00052-3","article-title":"Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides","volume":"13","author":"Fattom","year":"1995","journal-title":"Vaccine"},{"key":"B51","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1128\/IAI.60.2.584-589.1992","article-title":"Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate","volume":"60","author":"Fattom","year":"1992","journal-title":"Infect. Immun."},{"key":"B52","doi-asserted-by":"publisher","first-page":"7798","DOI":"10.1002\/anie.200903135","article-title":"Thiyl glycosylation of olefinic proteins: S-Linked glycoconjugate synthesis","volume":"48","author":"Floyd","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B53","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1086\/527396","article-title":"Protein D of Haemophilus influenzae: A protective nontypeable H. Influenzae antigen and a carrier for pneumococcal conjugate vaccines","volume":"46","author":"Forsgren","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1016\/j.vaccine.2009.06.013","article-title":"Preparation of bacterial polysaccharide-protein conjugates: Analytical and manufacturing challenges","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"715","DOI":"10.4161\/hv.19619","article-title":"Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM)","volume":"8","author":"Frasch","year":"2012","journal-title":"Hum. Vaccin Immunother."},{"key":"B56","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1084\/jem.54.3.431","article-title":"Chemo-immunological studies on conjugated carbohydrate-proteins: IV. The synthesis of thep-aminobenzyl ether of the soluble specific substance of type III pneumococcus and its coupling with protein","volume":"54","author":"Goebel","year":"1931","journal-title":"J. Exp. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1084\/jem.69.3.353","article-title":"Studies on antibacterial immunity induced by artificial antigens: I. Immunity to experimental pneumococcal infection with an antigen containing cellobiuronic acid","volume":"69","author":"Goebel","year":"1939","journal-title":"J. Exp. Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1086\/517407","article-title":"Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization","volume":"177","author":"Goldblatt","year":"1998","journal-title":"J. Infect. Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/INF.0b013e3180cc2c25","article-title":"Reconsideration of the use of meningococcal polysaccharide vaccine","volume":"26","author":"Granoff","year":"2007","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B60","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1574-695X.2005.00025.x","article-title":"Immunologic memory response induced by a meningococcal serogroup C conjugate vaccine using the P64k recombinant protein as carrier","volume":"46","author":"Guirola","year":"2006","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1128\/IAI.63.8.2805-2810.1995","article-title":"Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes","volume":"63","author":"Gupta","year":"1995","journal-title":"Infect. Immun."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1128\/IAI.60.8.3201-3208.1992","article-title":"Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin","volume":"60","author":"Gupta","year":"1992","journal-title":"Infect. Immun."},{"key":"B63","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.1128\/IAI.67.12.6375-6384.1999","article-title":"Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines","volume":"67","author":"Guttormsen","year":"1999","journal-title":"Infect. Immun."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1128\/IAI.66.5.2026-2032.1998","article-title":"Immunologic memory induced by a glycoconjugate vaccine in a murine adoptive lymphocyte transfer model","volume":"66","author":"Guttormsen","year":"1998","journal-title":"Infect. Immun."},{"key":"B65","doi-asserted-by":"publisher","first-page":"171","DOI":"10.15585\/mmwr.mm7207a2","article-title":"Typhoid fever surveillance, incidence estimates, and progress toward typhoid conjugate vaccine introduction - worldwide, 2018-2022","volume":"72","author":"Hancuh","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"B66","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1016\/j.vaccine.2015.06.102","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized phase I study","volume":"33","author":"Hatz","year":"2015","journal-title":"Vaccine"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1039\/c4cs00388h","article-title":"Towards the next generation of biomedicines by site-selective conjugation","volume":"45","author":"Hu","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"B68","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S1473-3099(17)30108-1","article-title":"Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: A randomised, single-blind, placebo-controlled phase 1b trial","volume":"17","author":"Huttner","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nchembio.2007.25","article-title":"Robust immune responses elicited by a fully synthetic three-component vaccine","volume":"3","author":"Ingale","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1084\/jem.163.2.262","article-title":"Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants","volume":"163","author":"Insel","year":"1986","journal-title":"J. Exp. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/0264-410x(91)90242-x","article-title":"Escherichia hermannii (ATCC 33651) polysaccharide-protein conjugates: Comparison of two conjugation methods for the induction of humoral responses in mice","volume":"9","author":"Jacques","year":"1991","journal-title":"Vaccine"},{"key":"B72","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1128\/IAI.69.2.787-793.2001","article-title":"Synthetic 6B di-tri-and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice","volume":"69","author":"Jansen","year":"2001","journal-title":"Infect. Immun."},{"key":"B73","first-page":"7","article-title":"Short-chain oligosaccharide protein conjugates as experimental pneumococcal vaccines","volume":"119","author":"Jansen","year":"2004","journal-title":"Indian J. Med. Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1023\/a:1007626510002","article-title":"Herd immunity and herd effect: New insights and definitions","volume":"16","author":"John","year":"2000","journal-title":"Eur. J. Epidemiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1590\/s0001-37652005000200009","article-title":"Vaccines based on the cell surface carbohydrates of pathogenic bacteria","volume":"77","author":"Jones","year":"2005","journal-title":"Acad Bras Cienc"},{"key":"B76","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1542\/peds.74.5.857","article-title":"Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: No evidence of immunologic tolerance or memory","volume":"74","author":"K\u00e4yhty","year":"1984","journal-title":"Pediatrics"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1182\/blood-2006-01-009282","article-title":"CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells","volume":"108","author":"Kelly","year":"2006","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/j.1365-2567.2008.02934.x","article-title":"Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine","volume":"127","author":"Kelly","year":"2009","journal-title":"Immunology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1086\/314590","article-title":"Self heat-shock protein (hsp60) peptide serves in a conjugate vaccine against a lethal pneumococcal infection","volume":"179","author":"K\u00f6nen-Waisman","year":"1999","journal-title":"J. Infect. Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1128\/IAI.65.6.2088-2093.1997","article-title":"Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker","volume":"65","author":"Kossaczka","year":"1997","journal-title":"Infect. Immun."},{"key":"B81","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.1128\/IAI.67.11.5806-5810.1999","article-title":"Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam","volume":"67","author":"Kossaczka","year":"1999","journal-title":"Infect. Immun."},{"key":"B82","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1021\/jo050934b","article-title":"A new method for conjugation of carbohydrates to proteins using an aminooxy-thiol heterobifunctional linker","volume":"70","author":"Kubler-Kielb","year":"2005","journal-title":"J. Org. Chem."},{"key":"B83","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/s0264-410x(96)00148-x","article-title":"The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity","volume":"15","author":"Laferri\u00e8re","year":"1997","journal-title":"Vaccine"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1016\/j.vaccine.2009.03.064","article-title":"Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface","volume":"27","author":"Lai","year":"2009","journal-title":"Vaccine"},{"key":"B85","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.vaccine.2008.11.065","article-title":"Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa","volume":"27","author":"Lee","year":"2009","journal-title":"Vaccine"},{"key":"B86","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/0264-410x(95)00195-7","article-title":"Activation of soluble polysaccharides with 1 cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents","volume":"14","author":"Lees","year":"1996","journal-title":"Vaccine"},{"key":"B87","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.vaccine.2005.08.096","article-title":"Versatile and efficient synthesis of protein-polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry","volume":"24","author":"Lees","year":"2006","journal-title":"Vaccine"},{"key":"B88","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2174\/1568005014605964","article-title":"Vaccines against polysaccharide antigens","volume":"1","author":"Lesinski","year":"2001","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","article-title":"Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine","volume":"294","author":"Lexau","year":"2005","journal-title":"Jama"},{"key":"B90","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/s0264-410x(99)00232-7","article-title":"Glycoprotein conjugate vaccines","volume":"17","author":"Lindberg","year":"1999","journal-title":"Vaccine"},{"key":"B91","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1086\/432582","article-title":"Carbohydrate moieties as vaccine candidates","volume":"41","author":"Lucas","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1001\/jama.283.21.2795","article-title":"Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial","volume":"283","author":"Maclennan","year":"2000","journal-title":"Jama"},{"key":"B93","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1586\/14760584.1.3.399","article-title":"Evolution of conjugate vaccines","volume":"1","author":"M\u00e4kel\u00e4","year":"2002","journal-title":"Expert Rev. Vaccines"},{"key":"B94","first-page":"43","article-title":"Safety and immunogenicity of two Haemophilus influenzae type b conjugate vaccines","volume":"94","author":"Matjila","year":"2004","journal-title":"S Afr. Med. J."},{"key":"B95","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1128\/iai.70.9.5107-5114.2002","article-title":"Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197","volume":"70","author":"Mawas","year":"2002","journal-title":"Infect. Immun."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/s0264-410x(98)00225-4","article-title":"Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein","volume":"16","author":"Michon","year":"1998","journal-title":"Vaccine"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/molecules23061451","article-title":"Protein carriers for glycoconjugate vaccines: History, selection criteria, characterization and new trends","volume":"23","author":"Micoli","year":"2018","journal-title":"Molecules"},{"key":"B98","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/vaccines8030540","article-title":"GMMA is a versatile platform to design effective multivalent combination vaccines","volume":"8","author":"Micoli","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B99","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/14760584.2019.1657012","article-title":"Glycoconjugate vaccines: Current approaches towards faster vaccine design","volume":"18","author":"Micoli","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"B100","doi-asserted-by":"publisher","first-page":"101433","DOI":"10.1016\/j.smim.2020.101433","article-title":"Outer membrane vesicle vaccines","volume":"50","author":"Micoli","year":"2020","journal-title":"Semin. Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10719-023-10100-3","article-title":"Strengths and weaknesses of pneumococcal conjugate vaccines","volume":"40","author":"Micoli","year":"2023","journal-title":"Glycoconj J."},{"key":"B102","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.vaccine.2010.11.022","article-title":"Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi","volume":"29","author":"Micoli","year":"2011","journal-title":"Vaccine"},{"key":"B103","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/nri1334","article-title":"T-cell-B-cell cooperation","volume":"4","author":"Mitchison","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/eji.1830010104","article-title":"The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation","volume":"1","author":"Mitchison","year":"","journal-title":"Eur. J. Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/eji.1830010103","article-title":"The carrier effect in the secondary response to hapten-protein conjugates. I. Measurement of the effect with transferred cells and objections to the local environment hypothesis","volume":"1","author":"Mitchison","year":"","journal-title":"Eur. J. Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/10_2018_71","article-title":"Interplay of carbohydrate and carrier in antibacterial glycoconjugate vaccines","volume":"175","author":"Moeller","year":"2021","journal-title":"Adv. Biochem. Eng. Biotechnol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1146\/annurev.iy.13.040195.003255","article-title":"T cell-independent antigens type 2","volume":"13","author":"Mond","year":"1995","journal-title":"Annu. Rev. Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1021\/bc500438h","article-title":"Tyrosine-directed conjugation of large glycans to proteins via copper-free click chemistry","volume":"25","author":"Nilo","year":"2014","journal-title":"Bioconjug Chem."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1021\/acschembio.5b00247","article-title":"Anti-group B Streptococcus glycan-conjugate vaccines using pilus protein GBS80 as carrier and antigen: Comparing lysine and tyrosine-directed conjugation","volume":"10","author":"Nilo","year":"","journal-title":"ACS Chem. Biol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1021\/acs.bioconjchem.5b00365","article-title":"Exploring the effect of conjugation site and chemistry on the immunogenicity of an anti-group B Streptococcus glycoconjugate vaccine based on GBS67 pilus protein and type V polysaccharide","volume":"26","author":"Nilo","year":"","journal-title":"Bioconjug Chem."},{"key":"B111","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1128\/IAI.69.3.1351-1357.2001","article-title":"Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel","volume":"69","author":"Passwell","year":"2001","journal-title":"Infect. Immun."},{"key":"B113","doi-asserted-by":"publisher","first-page":"5526","DOI":"10.1128\/IAI.67.10.5526-5529.1999","article-title":"Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice","volume":"67","author":"Pavliakova","year":"1999","journal-title":"Infect. Immun."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1128\/IAI.60.5.1826-1833.1992","article-title":"Synthetic trimer and tetramer of 3-beta-D-ribose-(1-1)-D-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys","volume":"60","author":"Peeters","year":"1992","journal-title":"Infect. Immun."},{"key":"B115","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1385\/1-59259-399-2:153","article-title":"Preparation of polysaccharide-conjugate vaccines","volume":"87","author":"Peeters","year":"2003","journal-title":"Methods Mol. Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.4049\/jimmunol.146.12.4308","article-title":"A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice","volume":"146","author":"Peeters","year":"1991","journal-title":"J. Immunol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJM198406143102404","article-title":"Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine","volume":"310","author":"Peltola","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1086\/652765","article-title":"Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: A phase 4 clinical trial","volume":"50","author":"Perrett","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B119","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1542\/peds.102.S1.252","article-title":"Responses of children immunized with capsular polysaccharide of hemophilus influenzae type b, by david H. Smith, MD, et al, pediatrics, 1973;52:637-644;and Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double-blind field study of 100 000 vaccinees 3 months to 5 years of age in Finland, by heikki Peltola, MD et al, pediatrics, 1977;60:730-737","volume":"102","author":"Peter","year":"1998","journal-title":"Pediatrics"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.4049\/jimmunol.0803141","article-title":"A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection","volume":"182","author":"Phalipon","year":"2009","journal-title":"J. Immunol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1542\/peds.2008-3645","article-title":"Booster vaccinations: Can immunologic memory outpace disease pathogenesis?","volume":"124","author":"Pichichero","year":"2009","journal-title":"Pediatrics"},{"key":"B122","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/s0264-410x(97)00146-1","article-title":"Serum antibody responses of weanling mice and two-year-old children to pneumococcal-type 6A-protein conjugate vaccines of differing saccharide chain lengths","volume":"16","author":"Pichichero","year":"1998","journal-title":"Vaccine"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: Characteristics, development, and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Hum. Vaccin Immunother."},{"key":"B124","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1172\/JCI91192","article-title":"T cells control the generation of nanomolar-affinity anti-glycan antibodies","volume":"127","author":"Polonskaya","year":"2017","journal-title":"J. Clin. Invest."},{"key":"B126","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1586\/erv.11.8","article-title":"Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines","volume":"10","author":"Poolman","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"B127","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1073\/pnas.96.9.5194","article-title":"Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1","volume":"96","author":"Pozsgay","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B128","doi-asserted-by":"publisher","first-page":"14478","DOI":"10.1073\/pnas.0706969104","article-title":"Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice","volume":"104","author":"Pozsgay","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B129","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/s0065-2318(01)56004-7","article-title":"Oligosaccharide-protein conjugates as vaccine candidates against bacteria","volume":"56","author":"Pozsgay","year":"2000","journal-title":"Adv. Carbohydr. Chem. Biochem."},{"key":"B130","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in england: Database analysis","volume":"326","author":"Ramsay","year":"2003","journal-title":"BMJ"},{"key":"B131","doi-asserted-by":"publisher","first-page":"eaat4615","DOI":"10.1126\/scitranslmed.aat4615","article-title":"Glycoconjugate vaccines: Principles and mechanisms","volume":"10","author":"Rappuoli","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1016\/s0264-410x(99)00092-4","article-title":"Size determination of bacterial capsular oligosaccharides used to prepare conjugate vaccines","volume":"17","author":"Ravenscroft","year":"1999","journal-title":"Vaccine"},{"key":"B133","first-page":"222","article-title":"Glycoconjugate vaccines","volume":"3","author":"Ravenscroft","year":"2000","journal-title":"Curr. Opin. Drug Discov. Devel"},{"key":"B134","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00006454-200102000-00007","article-title":"Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants","volume":"20","author":"Rennels","year":"2001","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B135","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1128\/CVI.00224-16","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: A single-blind, randomized phase I study","volume":"23","author":"Riddle","year":"2016","journal-title":"Clin. Vaccine Immunol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3390\/toxins6041385","article-title":"Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity","volume":"6","author":"Romano","year":"2014","journal-title":"Toxins (Basel)"},{"key":"B137","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1128\/CVI.00387-10","article-title":"Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi","volume":"18","author":"Rondini","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1574-695X.2006.00071.x","article-title":"Length of the linker and the interval between immunizations influences the efficacy of Vibrio cholerae O1, Ogawa hexasaccharide neoglycoconjugates","volume":"47","author":"Saksena","year":"2006","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1084\/jem.152.2.361","article-title":"Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates","volume":"152","author":"Schneerson","year":"1980","journal-title":"J. Exp. Med."},{"key":"B140","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1128\/IAI.45.3.582-591.1984","article-title":"Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates","volume":"45","author":"Schneerson","year":"1984","journal-title":"Infect. Immun."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.4049\/jimmunol.143.4.1259","article-title":"Antigenicity of dextran-protein conjugates in mice. Effect of molecular weight of the carbohydrate and comparison of two modes of coupling","volume":"143","author":"Sepp\u00e4l\u00e4","year":"1989","journal-title":"J. Immunol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/s0264-410x(99)00370-9","article-title":"Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) for use in protein-polysaccharide conjugate vaccines and immunological reagents. II. Selective crosslinking of proteins to CDAP-activated polysaccharides","volume":"18","author":"Shafer","year":"2000","journal-title":"Vaccine"},{"key":"B143","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1128\/IAI.69.1.297-306.2001","article-title":"Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization","volume":"69","author":"Shen","year":"2001","journal-title":"Infect. Immun."},{"key":"B144","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/s0264-410x(00)00226-7","article-title":"Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization","volume":"19","author":"Shen","year":"2000","journal-title":"Vaccine"},{"key":"B145","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/0264-410x(94)00042-l","article-title":"Development of a Guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines","volume":"13","author":"Siber","year":"1995","journal-title":"Vaccine"},{"key":"B146","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00006454-200206000-00013","article-title":"Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: The choice for a mixed carrier vaccine","volume":"21","author":"Sigurdardottir","year":"2002","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B147","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1128\/IAI.05484-11","article-title":"Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis","volume":"79","author":"Simon","year":"2011","journal-title":"Infect. Immun."},{"key":"B148","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B149","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.4049\/jimmunol.157.6.2229","article-title":"A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens","volume":"157","author":"Snapper","year":"1996","journal-title":"J. Immunol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"13198","DOI":"10.1002\/anie.201506112","article-title":"Sugar-protein connectivity impacts on the immunogenicity of site-selective Salmonella O-antigen glycoconjugate vaccines","volume":"54","author":"Stefanetti","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B151","doi-asserted-by":"publisher","first-page":"6432","DOI":"10.3390\/molecules27196432","article-title":"Impact and control of sugar size in glycoconjugate vaccines","volume":"27","author":"Stefanetti","year":"2022","journal-title":"Molecules"},{"key":"B152","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1016\/j.vaccine.2014.08.056","article-title":"Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines","volume":"32","author":"Stefanetti","year":"2014","journal-title":"Vaccine"},{"key":"B153","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/00006454-199405000-00007","article-title":"A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: Effect of polysaccharide size and linkage characteristics","volume":"13","author":"Steinhoff","year":"1994","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B154","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1073\/pnas.1816401115","article-title":"Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines","volume":"116","author":"Sun","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B155","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1128\/IAI.32.2.490-496.1981","article-title":"Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice","volume":"32","author":"Svenson","year":"1981","journal-title":"Infect. Immun."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1084\/jem.166.5.1510","article-title":"Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals","volume":"166","author":"Szu","year":"1987","journal-title":"J. Exp. Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"686","DOI":"10.4049\/jimmunol.170.2.686","article-title":"Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses","volume":"170","author":"Tangye","year":"2003","journal-title":"J. Immunol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1099\/jmm.0.039438-0","article-title":"Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design","volume":"61","author":"Terra","year":"2012","journal-title":"J. Med. Microbiol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"E1143","DOI":"10.1073\/pnas.1425005112","article-title":"Conjugate-like immunogens produced as protein capsular matrix vaccines","volume":"112","author":"Thanawastien","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B160","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1016\/j.vaccine.2013.07.078","article-title":"Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines","volume":"31","author":"Tontini","year":"2013","journal-title":"Vaccine"},{"key":"B161","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/j.vaccine.2016.06.039","article-title":"Preclinical studies on new proteins as carrier for glycoconjugate vaccines","volume":"34","author":"Tontini","year":"2016","journal-title":"Vaccine"},{"key":"B162","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"key":"B163","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1016\/j.vaccine.2008.05.073","article-title":"Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae","volume":"26","author":"Trotter","year":"2008","journal-title":"Vaccine"},{"key":"B164","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.earlhumdev.2010.08.010","article-title":"Challenges in immunisation against bacterial infection in children","volume":"86","author":"Tr\u00fcck","year":"2010","journal-title":"Early Hum. Dev."},{"key":"B165","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1128\/CVI.00059-06","article-title":"Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: What is its role in the maintenance of protection?","volume":"13","author":"Tsai","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/bs.mie.2017.06.032","article-title":"Glycoengineered outer membrane Vesicles as a platform for vaccine development","volume":"597","author":"Valguarnera","year":"2017","journal-title":"Meth Enzymol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1128\/IAI.59.8.2750-2757.1991","article-title":"Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: Influence of carriers and adjuvants on isotype distribution","volume":"59","author":"Van De Wijgert","year":"1991","journal-title":"Infect. Immun."},{"key":"B168","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1021\/acs.bioconjchem.5b00617","article-title":"A synthetic carbohydrate conjugate vaccine candidate against shigellosis: Improved bioconjugation and impact of alum on immunogenicity","volume":"27","author":"Van Der Put","year":"2016","journal-title":"Bioconjug Chem."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1126\/science.298.5599.1790","article-title":"N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli","volume":"298","author":"Wacker","year":"2002","journal-title":"Science"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/infdis\/jit800","article-title":"Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli","volume":"209","author":"Wacker","year":"2014","journal-title":"J. Infect. Dis."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/s0264-410x(02)00625-4","article-title":"Construction of designer glycoconjugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling","volume":"21","author":"Wang","year":"2003","journal-title":"Vaccine"},{"key":"B172","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1128\/IAI.60.11.4679-4686.1992","article-title":"Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine","volume":"60","author":"Watson","year":"1992","journal-title":"Infect. Immun."},{"key":"B173","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1016\/j.carres.2003.07.008","article-title":"Immunology of bacterial polysaccharide antigens","volume":"338","author":"Weintraub","year":"2003","journal-title":"Carbohydr. Res."},{"key":"B174","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1128\/IAI.66.5.2186-2192.1998","article-title":"Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy","volume":"66","author":"Wessels","year":"1998","journal-title":"Infect. Immun."},{"key":"B175","doi-asserted-by":"publisher","first-page":"13526","DOI":"10.1073\/pnas.0803195105","article-title":"Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis","volume":"105","author":"Xin","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B176","first-page":"637","article-title":"A bivalent MAPS vaccine induces protective antibody responses against Salmonella typhi and paratyphi A","volume":"11","author":"Zhang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B177","doi-asserted-by":"publisher","first-page":"13564","DOI":"10.1073\/pnas.1307228110","article-title":"Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B178","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1128\/IAI.47.2.421-428.1985","article-title":"Immunogenic properties of octasaccharide-protein conjugates derived from Klebsiella serotype 11 capsular polysaccharide","volume":"47","author":"Zigterman","year":"1985","journal-title":"Infect. Immun."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2023.1201693\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T13:15:29Z","timestamp":1729430129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2023.1201693\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":178,"alternative-id":["10.3389\/fmolb.2023.1201693"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2023.1201693","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"article-number":"1201693"}}